Patents by Inventor Benedicte Delouvrie
Benedicte Delouvrie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9657008Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: GrantFiled: August 31, 2015Date of Patent: May 23, 2017Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Benedicte Delouvrie, Craig Steven Harris, Christine Marie Paul Lambert-Van der Brempt, Gilles Ouvry, Gary Patrick Reid, David Berry, Gary Peter Tomkinson
-
Publication number: 20160137634Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: August 31, 2015Publication date: May 19, 2016Applicant: AstraZeneca ABInventors: Bernard Christophe Barlaam, Benedicte Delouvrie, Craig Steven Harris, Christine Marie, Paul Lambert-Van der Brempt, Gilles Ouvry, Gary Patrick Reid, David Berry, Gary Peter Tomkinson
-
Patent number: 9156831Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: GrantFiled: January 22, 2014Date of Patent: October 13, 2015Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Benedicte Delouvrie, Gilles Ouvry, Christine Marie Paul Lambert-Van Der Brempt, Craig Steven Harris, David Berry, Gary Peter Tomkinson, Gary Patrick Reid
-
Publication number: 20140206700Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: January 22, 2014Publication date: July 24, 2014Applicant: ASTRAZENECA ABInventors: Bernard Christophe BARLAAM, Benedicte DELOUVRIE, Gilles OUVRY, Christine Marie, Paul, LAMBERT-VAN DER BREMPT, Craig Steven HARRIS, David BERRY, Gary Peter TOMKINSON, Gary Patrick REID
-
Patent number: 8017611Abstract: The invention concerns pyridine and pyrazine derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of W, G1, G2, G3, G4, J, Ring A, n and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.Type: GrantFiled: October 23, 2008Date of Patent: September 13, 2011Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Craig Steven Harris, Christine Marie Paul Lambert, Gilles Ouvry, Justin Fairfield Bower, Benedicte Delouvrie, Gary Fairley, Jon James Gordon Winter
-
Patent number: 7632840Abstract: A quinazoline derivative of the formula I: wherein: R1, R2, R3, R3a, R4, R5, R5a R6, R7, a, m and p are as defined in the description. Also claimed are pharmaceutical compositions containing the quinazoline derivative, the use of the quinazoline derivatives as medicaments and processes for the preparation of the quinazoline derivative. The quinazoline derivatives of formula I, are useful in the treatment of hyperproliferative disorders such as a cancer.Type: GrantFiled: January 31, 2005Date of Patent: December 15, 2009Assignee: AstraZeneca ABInventors: Benedicte Delouvrie, Craig Steven Harris, Laurent Francois Andre Hennequin, Christopher Thomas Halsall, Janet Elizabeth Pease, Peter Mark Smith
-
Publication number: 20090203663Abstract: The present invention relates to compounds that inhibit a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.Type: ApplicationFiled: February 7, 2007Publication date: August 13, 2009Applicant: AstraZeneca ABInventors: Jean Claude Arnould, Benedicte Delouvrie, Jason Grant Kettle
-
Patent number: 7547722Abstract: The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.Type: GrantFiled: May 22, 2007Date of Patent: June 16, 2009Assignee: AstraZeneca ABInventors: Kevin Michael Foote, Zbigniew Stanley Matusiak, Alexander Graham Dossetter, Jean Claude Arnould, Maryannick Andree Lamorlette, Benedicte Delouvrie, Annie Hamon
-
Publication number: 20090118305Abstract: The invention concerns pyridine and pyrazine derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of W, G1, G2, G3, G4, J, Ring A, n and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.Type: ApplicationFiled: October 23, 2008Publication date: May 7, 2009Applicant: ASTRAZENECA ABInventors: Bernard Christophe Barlaam, Craig Steven Harris, Christine Marie Paul Lambert, Gilles Ouvry, Justin Fairfield Bower, Benedicte Delouvrie, Gary Fairley, Jon James Gordon Winter
-
Publication number: 20090062267Abstract: The present invention relates to compounds that inhibit a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.Type: ApplicationFiled: January 29, 2008Publication date: March 5, 2009Applicant: ASTRAZENECA ABInventors: Jean-Claude Arnould, Benedicte Delouvrie, Christine Marie Paul Lambert-Van Der Brempt
-
Publication number: 20080255183Abstract: The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to a5b1 antagonists that also exhibit appropriate selectivity profile(s) against other integrins.Type: ApplicationFiled: April 11, 2008Publication date: October 16, 2008Applicant: ASTRAZENECA ABInventors: Jean-Claude ARNOULD, Benedicte DELOUVRIE, Craig Steven HARRIS
-
Publication number: 20080182842Abstract: The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.Type: ApplicationFiled: January 29, 2008Publication date: July 31, 2008Applicant: ASTRAZENECA ABInventors: Jean-Claude Arnould, Benedicte Delouvrie, Christine Marie Paul Lambert-Van Der Brempt
-
Publication number: 20080045517Abstract: The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.Type: ApplicationFiled: May 22, 2007Publication date: February 21, 2008Applicant: AstraZeneca ABInventors: Kevin Foote, Zbigniew Matusiak, Alexander Dossetter, Jean Claude Arnould, Maryannick Lamorlette, Benedicte Delouvrie, Annie Hamon
-
Publication number: 20080045521Abstract: The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to a5b1 antagonists that also exhibit appropriate selectivity profile(s) against other integrins.Type: ApplicationFiled: May 10, 2007Publication date: February 21, 2008Applicant: AstraZeneca ABInventors: Jean-Claude Arnould, Benedicte Delouvrie, Richard Ducray, Christine Marie Paul Van Der Brempt
-
Publication number: 20070293490Abstract: A quinazoline derivative of the formula (I) wherein: R1, R2, R3, R3a, R4, R5, R5a R6, R7, a, m and p are as defined in the description. Also claimed are pharmaceutical compositions containing the quinazoline derivative, the use of the quinazoline derivatives as medicaments and processes for the preparation of the quinazoline derivative. The quinazoline derivatives of formula (I), are useful in the treatment of hyperproliferative disorders such as a cancer.Type: ApplicationFiled: January 31, 2005Publication date: December 20, 2007Inventors: Benedicte Delouvrie, Craig Harris, Laurent Hennequin, Christopher Halsall, Janet Pease, Peter Smith
-
Patent number: 7268158Abstract: The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.Type: GrantFiled: May 1, 2006Date of Patent: September 11, 2007Assignee: AstraZeneca ABInventors: Kevin Michael Foote, Zbigniew Matusiak, Alexander Graham Dossetter, Jean Claude Arnould, Maryannick Andree Lamorlette, Benedicte Delouvrie, Annie Hamon
-
Patent number: 7132442Abstract: The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.Type: GrantFiled: August 19, 2003Date of Patent: November 7, 2006Assignee: AstraZeneca ABInventors: Kevin Michael Foote, Zbigniew Matusiak, Alexander Graham Dossetter, Jean Claude Arnould, Maryannick Andree Lamorlette, Benedicte Delouvrie, Annie Hamon
-
Publication number: 20060235067Abstract: The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.Type: ApplicationFiled: May 1, 2006Publication date: October 19, 2006Applicant: AstraZeneca ABInventors: Kevin Foote, Zbigniew Matusiak, Alexander Dossetter, Jean Claude Arnould, Maryannick Lamorlette, Benedicte Delouvrie, Annie Hamon
-
Publication number: 20060004082Abstract: The invention relates to a group of novel thieno-pyrrole compounds of Formula (1): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.Type: ApplicationFiled: August 19, 2003Publication date: January 5, 2006Applicant: AstraZenecaInventors: Kevin Foote, Zbigniew Matusiak, Alexander Dossetter, Jean Arnould, Maryannick Lamorlette, Benedicte Delouvrie, Annie Hamon